Adverse Events. Subsequent to the date hereof, there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the New York Stock Exchange, the NASDAQ National Market or the NASDAQ Global Market, (ii) a general moratorium on commercial banking activities in the People’s Republic of China or New York, (iii) the outbreak or escalation of hostilities involving the United States or the People’s Republic of China or the declaration by the United States or the People’s Republic of China of a national emergency or war if the effect of any such event specified in this clause (iii) in your reasonable judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus, or (iv) such a material adverse change in general economic, political, financial or international conditions affecting financial markets in the United States or the People’s Republic of China having a material adverse impact on trading prices of securities in general, as, in your reasonable judgment, makes it impracticable or inadvisable to proceed with the public offering of the Shares or the delivery of the Shares on the terms and in the manner contemplated in the Prospectus.
Adverse Events. Promptly inform the Bank of the occurrence of any Event of Default or Default, or of any other occurrence which has or could reasonably be expected to have a materially adverse effect upon the Borrower's business, properties, or financial condition or upon the Borrower's ability to comply with its obligations under the Documents.
Adverse Events. 1.5 Nežádoucí příhody Investigator shall report adverse events and serious adverse events as directed in the Protocol and by Applicable Laws and regulations. Investigator shall cooperate with Sponsor in its efforts to follow up on any adverse events. Site shall comply with its LEC reporting obligations. Sponsor will promptly report to Site any finding that could affect the safety of participants or their willingness to continue participation in the Study, influence the conduct of the Study, or alter Site’s LEC approval to continue the Study. Zkoušející oznámí nežádoucí příhody a závažné nežádoucí příhody v souladu s požadavky Protokolu a příslušnými právními předpisy a nařízeními. Zkoušející se zavazuje, že bude spolupracovat se Zadavatelem v souvislosti s jeho úsilím vynaloženém v rámci kontrolního procesu ve vztahu k jakékoli nežádoucí příhodě. Místo provádění klinického hodnocení bude jednat v souladu s oznamovacími povinnostmi vyžadovanými jeho LEK. Zadavatel bez zbytečného odkladu vyrozumí Místo výkonu klinického hodnocení, LEK a CRO, ohledně jakéhokoli zjištění, jež je způsobilé ovlivnit bezpečnost účastníků či jejich vůli a ochotu pokračovat v účasti ve Studii, mít vliv na provádění Studie, či změnit vydané souhlasné stanovisko LEK Místa provádění klinického hodnocení vztahující se k pokračování ve Studii.
Adverse Events. The Investigator shall report adverse events and serious adverse events as directed in the Protocol and by Applicable Laws and regulations. The Investigator and Institution shall cooperate with Sponsor in its efforts to follow-up on any adverse events. Institution and Investigator shall comply with its EC reporting obligations. Sponsor will promptly report to the Institution and Investigator, the Institution’s EC, and CRO, any finding that could affect the safety of participants or their willingness to continue participation in the Study, influence the conduct of the Study, or alter the Institution’s IEC approval to continue the Study.
Adverse Events. Pharmacy must report adverse events to the ImmTrac Texas Immunization Registry and Authorizing Physician.15 Pharmacy must also notify the patient’s primary care provider of the administration of
Adverse Events. Within ninety (90) days after the Effective Date, the Parties will enter into a pharmacovigilance agreement, which upon such execution will be attached as an exhibit hereto and hereby incorporated into this Agreement by reference (the “Pharmacovigilance Agreement”). The Parties shall comply with the provisions of such agreement. AstraZeneca shall maintain and will be the recognized holder of a global safety database for Adverse Event reports related to the Collaboration Product. Unless otherwise agreed to by the Parties, AstraZeneca will respond to all safety inquiries regarding Collaboration Products in the Field in the Territory.
Adverse Events. Subject to the balance of this section 9, First Gas will use reasonable endeavours to avoid curtailing the taking of Gas at a Delivery Point. However, First Gas may curtail the taking of Gas (or the ability to take Gas) at a Delivery Point to the extent it determines to be necessary, where: an Emergency is occurring or is imminent; a Force Majeure Event has occurred or is continuing; a breach of any Security Standard Criteria and/or a Critical Contingency would otherwise occur; a Shipper’s TSA or Supplementary Agreement, Existing Supplementary Agreement, GTA, or the Allocation Agreement, expires or is terminated or is not executed; this Agreement expires or is terminated, either in total or in relation to that Delivery Point; it is performing, or is to perform, scheduled or unscheduled Maintenance pursuant to section 9.2 or section 9.3; and/or it does so to maintain the Target Taranaki Pressure pursuant to this Agreement and/or section 3.33 of the Code, provided that in relation to the events described in this section 9.1(a) or (b), First Gas shall use reasonable endeavours to minimise the period of curtailment.
Adverse Events. Between the date hereof and each Closing Date, the Company shall not have sustained any loss on account of fire, explosion, flood, accident, calamity or any other cause, of such character as materially adversely affects its business or property considered as an entity, whether or not such loss is covered by insurance.
Adverse Events. Beglend shall be responsible for reporting to the appropriate regulatory authorities all adverse events related to the use of the Products worldwide. Adverse events related to the use of the Products worldwide shall be recorded in Beglend's standard database and during the period of research into and development of Products, the parties will coordinate their efforts to assure that all adverse events are reported properly.
Adverse Events. Promptly after the occurrence, or failure to occur, of any event, the occurrence or failure of which (a) would result in an IXC Material Adverse Effect or could reasonably be expected to result in an IXC Material Adverse Effect or materially adversely affect the ability of IXC to perform any of its obligations under this Agreement, (b) if known as of the date of this Agreement, would have been required to be disclosed to Network, or (c) causes any representation or warranty of IXC contained in this Agreement or any Schedule hereto to be untrue or inaccurate in any material respect at any time from the date of this Agreement to and including the Closing Date, IXC shall provide to Network all relevant information related thereto.